In addition, approximately 2%–8% of patients with CLL have detected FBW7 mutations, mainly missense mutations, affecting the WD40 domain required for substrate binding, and the mutation sites detected at R465L, R465H and G423V (65–67). Here, FBXW7 is linked to B-cell chronic lymphocytic leukemia.